Evidence map›Paper›PMID 27917074›Full record

ArticleGastroenterology & hepatology2016

Medical Management of Metabolic Complications of Liver Transplant Recipients.

Abbey Barnard, Peter Konyn, Sammy Saab

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Gastroenterology & hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Metabolic syndrome after liver transplantation: A silent threat to long-term success.World journal of gastrointestinal pharmacology and therapeutics · 2025
    Review
  2. Bariatric surgery, obesity and liver transplantation.Translational gastroenterology and hepatology · 2022
    Review
  3. Review
  4. Article
  5. Quality of life 5 years following liver transplantation.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Abbey BarnardDr Barnard is a resident physician in the Department of Internal Medicine at the University of California, Los Angeles in Los Angeles, California. Mr Konyn is a medical student at the David Geffen School of Medicine at the University of California, Los Angeles. Dr Saab is a professor in the Departments of Internal Medicine and Surgery at the University of California, Los Angeles.
Peter KonynDr Barnard is a resident physician in the Department of Internal Medicine at the University of California, Los Angeles in Los Angeles, California. Mr Konyn is a medical student at the David Geffen School of Medicine at the University of California, Los Angeles. Dr Saab is a professor in the Departments of Internal Medicine and Surgery at the University of California, Los Angeles.
Sammy SaabDr Barnard is a resident physician in the Department of Internal Medicine at the University of California, Los Angeles in Los Angeles, California. Mr Konyn is a medical student at the David Geffen School of Medicine at the University of California, Los Angeles. Dr Saab is a professor in the Departments of Internal Medicine and Surgery at the University of California, Los Angeles.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Improved short- and long-term survival of liver transplant recipients has led to increased focus on complications of both the early and late posttransplant periods. A variety of metabolic complications have been observed in the post-orthotopic liver transplant population, including hypertension, hyperlipidemia, obesity, diabetes mellitus, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis. Although only a small proportion of patients experience metabolic complications prior to transplantation, the prevalence of these complications posttransplantation reaches or exceeds that of the general population. This is of particular concern, as cardiovascular disease is the second leading cause of death in the late transplant period. A number of mechanisms mediate these metabolic complications, including reversal of cirrhosis pathophysiology, patient lifestyle factors, and immunosuppressive medications. Titration and modification of immunosuppression have been demonstrated to improve and sometimes even eliminate these conditions. Therefore, given the multiple etiologies contributing to the metabolic derangements, an effective management approach must incorporate lifestyle modifications, immunosuppression titration, and medical management. Best practices and understanding of the mechanisms underlying these complications allow for discussion of initial therapies and strategies; however, further study is necessary to determine the optimal management of metabolic complications over time.

Indexed as

Liver transplantlong-term caremedical managementmetabolic complications

Identifiers

PMID27917074
PMCPMC5114502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.